S11
Track-Topic
ESTRO 2026
Digital Poster Highlight 2173
Quality of life of patients treated with “High-Five” accelerated partial breast irradiation (HiFi-APBI): 2- year report of a prospective trial. Adam Kluska 1 , Artur Chyrek 1,2 , Wojciech Burchardt 1,2 , Adam Chiche ł 1 1 Brachytherapy, Greater Poland Cancer Centre, Poznan, Poland. 2 Department of Electroradiology, Poznan University of Medical Science, Poznan, Poland
Purpose/Objective: Our study evaluated the impact of adjuvant
accelerated partial breast irradiation (APBI) using HDR brachytherapy on the health-related quality of life (HRQL) of patients with early-stage breast cancer after breast conserving surgery. Material/Methods: A total of 147 patients were enrolled in a prospective clinical trial between October 2021 and December 2023. Treatment was performed using HDR brachytherapy and was given during 3 days in 5 fractions of 5,4 Gy, to a total dose of 27.0 Gy. The primary endpoint of trial was to assess early and late toxicities of novel fractionation scheme. As one of the secondary endpoints, HRQL was assessed using QLQ- C30 questionnaire, with breast cancer specific HRQL module - EORTC QLQ-BR23 before APBI, administered before APBI, and then at 1 month, 3 months, and 6 months, year after treatment, and annually thereafter. Both questionnaires contain functional scales – where higher score represents better functioning and symptom scales where higher score represents higher level of symptoms. This analysis presents a preliminary report of the medium-term (2 years) quality of life of 129 patients who completed 2 years of follow-up. Repeated measures ANOVA was used to compare HRQL scores between timepoints. A p-value below 0.05 was considered statistically significant. Results: There was statistically significant change in mean of role functioning scale (p=0.016), cognitive functioning scale (p=0.017), and social functioning scale (p=0.001), as well as increase of constipation symptoms scale (p=0.004) and dyspnea scale (p<0.001) assessed in EORTC QLQ-C30 scale. The analysis of EORTC QLQ- BR23 module scales showed increase in the body image functional scale (BRBI, Fig. 21) (p=0.009), future perspective functional scale (BRFU) (p<0.001). In symptoms scales there was increase in systemic therapy side effects scale (p<0.001) and decrease of breast symptoms (BRBS, Fig.2) (p=0<001). There were no other statistically significant changes in either functional or symptom scales of the QLQ-C30 and BR23 questionnaires.
Fig 1 Analysis of BRBI scores (EORTC BR23) before treatment (timepoint I), at 1 month (II), 3 months (III), 6 months (IV), 1 year (V), and 2 years after HiFi-APBI
Fig 2 Analysis of BRBS scores (EORTC BR23) before treatment (I), at 1 month (II), 3 months (III), 6 months (IV), 1 year (V), and 2 years after HiFi-APBI Conclusion: There was no deterioration in the medium-term HRQL of patients treated with 5 x 5,4 Gy HDR APBI. We observed increased symptoms only in scales linked with systemic therapy and, most importantly, a decrease in breast-related symptoms after treatment. Keywords: APBI, QoL, Breast Cancer Doubly accelerated partial breast irradiation after breast-conserving surgery: 2-year toxicity and cosmetic results of High Five (HiFi) APBI study. Adam Chichel 1 , Adam Kluska 1 , Artur Jan Chyrek 1,2 , Wojciech Maria Burchardt 1,2 1 Brachytherapy, Greater Poland Cancer Centre, Poznan, Poland. 2 Electroradiology, Poznan University of Medical Sciences, Poznan, Poland Purpose/Objective: A prospective mono-institutional non-randomized open-label study (NTC05142202) has been carried out Digital Poster Highlight 2776
Made with FlippingBook - Share PDF online